Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]

This article discusses some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The art...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley B, Leach, Mariah Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625413/
https://www.ncbi.nlm.nih.gov/pubmed/37927492
http://dx.doi.org/10.2147/OARRR.S443235
Descripción
Sumario:This article discusses some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The article also covers the difference between a generic medicine and a biosimilar, and the clinical evidence to support the safety and efficacy of adalimumab biosimilars in patients with rheumatoid arthritis.

Ejemplares similares